Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
US Ecology Inc. (NASDAQ: ECOL) shares spiked 7.69 percent to close at $38.49 a share Tuesday. The stock traded between $37.10 and $39.67 on volume 527,626 shares traded. The company announced that it has acquired EQ, an environmental services and waste management company, for $465.0 million. Shares of US Ecology are up approximately 4.0 percent year-to-date.
Get more information on US Ecology free access to the in-depth equity report at: www.FiveStarEquities.com/ECOL
MannKind Corporation (NASDAQ: MNKD) shares increased 3.48 percent to close at $6.54 a share Tuesday. The stock traded between $6.30 and $6.58 on volume of 10.06 million shares traded. The company announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA to July 15th. Shares of MannKind are up approximately 25.0 percent year-to-date.
Get more information on MannKind and free access to the in-depth equity report at: www.FiveStarEquities.com/MNKD
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares declined 1.18 percent to close at $50.90 a share Tuesday. The stock traded between $49.76 and $52.02 on volume of 12.29 million shares traded. The company announced the approval of a generic version of the heart medication Lovazain the United States. Shares of Teva Pharmaceutical are up approximately 27.0 percent year-to-date.
Get more information on Teva Pharmaceutical and free access to the in-depth equity report at: www.FiveStarEquities.com/TEVA
Zogenix, Inc. (NASDAQ: ZGNX) shares gained 5.28 percent to close at $2.59 a share Tuesday. The stock traded between $2.36 and $2.63 on volume 2.34 million shares traded. The company has requested a temporary restraining order against execution of the executive order recently announced by Governor Deval Patrick that prohibits the sale of Zohydro™ ER. Shares of Zogenix are down approximately 25.0 percent year-to-date.
Get more information on Zogenix and free access to the in-depth equity report at: www.FiveStarEquities.com/ZGNX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]